Acute Myocardial Infarction Market Set for Steady Growth Through 2034 - Market Insight, Epidemiology, and Forecast | DelveInsight

Acute Myocardial Infarction (AMI), commonly known as a heart attack, continues to be one of the leading causes of morbidity and mortality worldwide. Characterized by the interruption of blood flow to the heart muscle, AMI often results from coronary artery blockage due to atherosclerotic plaque rupture. Despite improvements in emergency care and secondary prevention strategies, AMI remains a critical burden on global healthcare systems.

DelveInsight's latest report, "Acute Myocardial Infarction - Market Insight, Epidemiology, and Market Forecast - 2034," provides a comprehensive analysis of the AMI landscape across major markets, including the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. The report offers detailed epidemiological insights segmented by age, gender, comorbidities, and risk factors, along with historical trends and long-term forecasts.

The AMI treatment paradigm has evolved considerably with the adoption of advanced interventional techniques such as percutaneous coronary intervention (PCI), widespread use of antiplatelet therapies, and improved cardiac rehabilitation protocols. However, timely diagnosis, access to care, and adherence to long-term therapy remain key challenges, particularly in aging populations and low-resource settings.

The AMI market is expected to grow steadily through 2034, driven by increasing prevalence, rising cardiovascular risk factors such as diabetes and obesity, and innovation in diagnostics, pharmacological therapies, and regenerative approaches. Ongoing R&D in cardioprotective agents, next-generation stents, and cell-based therapies further underscores the evolving therapeutic landscape.

DelveInsight anticipates a dynamic and opportunity-rich market as healthcare systems continue to strengthen cardiac care infrastructure and emphasize preventive cardiology. With greater awareness, precision diagnostics, and emerging treatment strategies, the AMI market is poised for notable advancement over the next decade.

Request a sample and uncover the latest breakthroughs shaping the acute myocardial infarction market landscape and future outlook @ https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Some of the key insights of the Acute Myocardial Infarction Market Report:
• The acute myocardial infarction market in the 7MM was valued at USD 1.6 billion in 2023 and is expected to grow through 2034.
• In 2024, there were around 1.48 million incident AMI cases in the 7MM, with numbers projected to rise.
• The US had the highest AMI incidence, with approximately 829K cases in 2024.
• NSTEMI accounted for ~75% of AMI cases in the US, with ~611K NSTEMI and ~217K STEMI cases.
• With the approval of AGEPHA Pharma's LODOCO, patients with residual inflammatory risk now have the first FDA-approved option to reduce cardiovascular risk.
• Currently, no approved therapies target inflammation during PCI in STEMI, but Faraday's FDY-5301 and Kancera's KAND567 show promise in this space.
• In March 2025, Powerful Medical, a leader in AI-driven cardiovascular diagnostics, announced that its PMcardio STEMI AI ECG model has received Breakthrough Device Designation from the US FDA. This recognition highlights PMcardio's innovation in detecting ST-elevation myocardial infarction (STEMI) and STEMI equivalents, conditions that require urgent intervention.
• In September 2024, the FDA approved flurpiridaz F-18 (Flyrcado; GE HealthCare), a new radioactive tracer for positron emission tomography (PET) myocardial perfusion imaging. This is the first new cardiac PET radiotracer in decades and is expected to enhance testing growth. It will be used to evaluate myocardial ischemia or infarction in adults, joining existing tracers like rubidium-82 and N-13 ammonia, approved in 1989 and 2000, respectively.
• Emerging therapies for acute myocardial infarction include Selatogrel, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others.
• Key companies involved in the treatment of acute myocardial infarction include Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, and others.

To know in detail about the acute myocardial infarction market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute Myocardial Infarction Overview
Acute Myocardial Infarction (AMI), commonly referred to as a heart attack, is a life-threatening cardiovascular event that occurs when blood flow to a part of the heart muscle is abruptly blocked, typically due to a blood clot in a coronary artery. This interruption in blood supply leads to ischemia and damage or death of the heart tissue. AMI is most often caused by underlying coronary artery disease and is associated with major risk factors such as hypertension, smoking, diabetes, hyperlipidemia, and a sedentary lifestyle. Symptoms commonly include chest pain, shortness of breath, fatigue, and in some cases, silent or atypical presentations-especially in women and elderly individuals.

Despite significant advances in emergency care and cardiac intervention, AMI remains a leading cause of morbidity and mortality globally. Timely diagnosis and rapid intervention, such as percutaneous coronary intervention (PCI) or thrombolytic therapy, are crucial for improving outcomes. Current treatment strategies focus on restoring blood flow, minimizing heart damage, and preventing recurrence through the use of medications like antiplatelets, beta-blockers, ACE inhibitors, and statins. With the increasing burden of cardiovascular risk factors worldwide, the healthcare community continues to emphasize preventive cardiology and long-term management to curb the incidence and impact of acute myocardial infarction.

Get a free sample for the acute myocardial infarction market forecast, size & share analysis report: https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute Myocardial Infarction Epidemiology
The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.

Acute Myocardial Infarction Epidemiology Segmentation:
The acute myocardial infarction market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:
• Total incident cases of AMI
• Type-specific incidence of AMI
• Gender-specific incidence of AMI

Acute Myocardial Infarction Drugs Uptake and Pipeline Development Activities
The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for acute myocardial infarction throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments.

The Therapeutics Assessment further highlights the acute myocardial infarction drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction.

Additionally, the report provides an in-depth overview of the current therapeutic pipeline for acute myocardial infarction, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of acute myocardial infarction therapeutics.

Explore how emerging acute myocardial infarction therapies are aligning with evolving patient populations @ https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute Myocardial Infarction Market Outlook
The Acute Myocardial Infarction (AMI) market in the 7MM was valued at approximately USD 1.6 billion in 2023 and is projected to grow steadily through 2034. The United States is expected to lead the market in terms of revenue, while among the EU4 and the UK, Germany is anticipated to generate the highest market share during the forecast period.

The current AMI treatment landscape is segmented into key therapeutic classes, including antiplatelet agents, anticoagulants, vasodilators, beta-blockers, statins, ACE inhibitors, ARBs, and calcium channel blockers. These categories reflect prevailing treatment practices across the 7MM, with minor variations in prescribing patterns by region.

Acute Myocardial Infarction Market Drivers
• The growing incidence of hypertension, diabetes, obesity, and sedentary lifestyles is directly contributing to an increased number of AMI cases worldwide. This surge is fueling demand for effective diagnostics, emergency interventions, and long-term treatment solutions, driving market growth.
• Innovations in cardiac biomarkers, imaging techniques (such as cardiac MRI and CT), and minimally invasive procedures like drug-eluting stents and catheter-based interventions are improving outcomes and expanding the treatment landscape for AMI.

Acute Myocardial Infarction Market Barriers
• Advanced treatments and procedures for AMI, including PCI and long-term pharmacological therapy, can be expensive and less accessible in low- and middle-income countries, limiting widespread adoption and timely intervention.
• Lack of awareness about early AMI symptoms, particularly in high-risk but underserved populations, often leads to delayed hospital visits, which significantly impacts treatment effectiveness and overall survival rates.

Scope of the Acute Myocardial Infarction Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].
• Key Acute Myocardial Infarction Companies: Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, and others.
• Key Acute Myocardial Infarction Therapies: Selatogrel, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others.
• Acute Myocardial Infarction Therapeutic Assessment: Acute Myocardial Infarction currently marketed, and Acute Myocardial Infarction emerging therapies.
• Acute Myocardial Infarction Market Dynamics: Acute Myocardial Infarction market drivers and Acute Myocardial Infarction market barriers.
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies.
• Acute Myocardial Infarction Unmet Needs, KOL's views, Analyst's views, Acute Myocardial Infarction Market Access and Reimbursement.

To learn more about acute myocardial infarction companies working in the treatment market, visit @ https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Acute Myocardial Infarction Market Report Introduction
2. Executive Summary for Acute Myocardial Infarction
3. SWOT analysis of Acute Myocardial Infarction
4. Acute Myocardial Infarction Patient Share (%) Overview at a Glance
5. Acute Myocardial Infarction Market Overview at a Glance
6. Acute Myocardial Infarction Disease Background and Overview
7. Acute Myocardial Infarction Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute Myocardial Infarction
9. Acute Myocardial Infarction Current Treatment and Medical Practices
10. Acute Myocardial Infarction Unmet Needs
11. Acute Myocardial Infarction Emerging Therapies
12. Acute Myocardial Infarction Market Outlook
13. Country-Wise Acute Myocardial Infarction Market Analysis (2020-2034)
14. Acute Myocardial Infarction Market Access and Reimbursement of Therapies
15. Acute Myocardial Infarction Market Drivers
16. Acute Myocardial Infarction Market Barriers
17. Acute Myocardial Infarction Appendix
18. Acute Myocardial Infarction Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.